The transcription factor NF-κB regulates multiple aspects of innate and adaptive immune
functions and serves as a pivotal mediator of inflammatory response. In the first part of this …

Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Insulin-dependent diabetes may occur in patients with cancers who are treated with
checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two …

Autoimmune polyendocrinopathies are traditionally divided into two distinct syndromes,
autoimmune polyendocrine syndrome type 1 and 2 (APS-1 and-2). The first is a monogenic …

Advances in cancer therapy in the past few years include the development of medications
that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and …

Background: Cancer immunotherapy with checkpoint inhibitors (CPIs) is associated with
frequent immune-related adverse events (irAEs) and is often not recommended for patients …

Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …

Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment.
However, immune-related adverse effects (irAEs) have also increased with the exponential …

Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the
regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either …